Sustained release vaccine platforms for enhanced humoral immunity
June 5-9, 2018
Vaccines aim to modulate the immune system to elicit a sufficiently robust, yet targeted, immune response with specifiable immune cell phenotypes.1,2 Failure of a single vaccine administration to elicit such a response likely arises from inappropriate temporal control over antigen/adjuvant presentation and immune cell activation.2 Recent work demonstrates the potential for sustained, low-level presentation of antigens and adjuvants for just over a week to yield more potent and long-lasting immunity.3
Please download the file below for full content.
Gillie Agmon, Emily Gale, Caitlin Maikawa, Anthony Yu, and Eric Appel, "Sustained release vaccine platforms for enhanced humoral immunity" in "Nanotechnology in Medicine II: Bridging Translational in vitro and in vivo Interfaces", Millicent Sullivan, PhD, University of Delaware, USA Josué Sznitman, Dr. Sc., Technion-Israel Institute of Technology, Israel Lola Eniola-Adefeso, PhD, University of Michigan, USA Srivatsan Kidambi, PhD, University of Nebraska - Lincoln, USA Eds, ECI Symposium Series, (2018). http://dc.engconfintl.org/nanotech_med_ii/1